<DOC>
	<DOCNO>NCT02329327</DOCNO>
	<brief_summary>The purpose study evaluate hemostatic efficacy andexanet alfa patient receive factor Xa inhibitor experience acute major bleed . The safety andexanet also study .</brief_summary>
	<brief_title>A Study Patients With Acute Major Bleeding Evaluate Ability Andexanet Alfa Reverse Anticoagulation Effect Direct Indirect Oral Anticoagulants</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Inclusion : 1 . Acute major bleed episode require urgent reversal anticoagulation ; define least one following : Acute bleed potentially lifethreatening , OR Acute bleed associate fall hemoglobin level ≥2 g/dL , OR Acute bleed associate hemoglobin level ≤8 g/dL baseline hemoglobin available , OR Acute bleed critical area organ intraspinal , pericardial , intracranial . 2 . If bleeding intracranial intraspinal , patient must undergo head CT MRI scan demonstrate bleeding . 3 . Patient receive believe receive one follow within 18 hour prior andexanet administration : apixaban , rivaroxaban , edoxaban enoxaparin . 4 . For patient intracranial bleeding , must reasonable expectation andexanet treatment commence within 2 hour baseline image evaluation . Exclusion : 1 . The patient schedule undergo surgery le 12 hour , exception minimally invasive surgery/procedures . 2 . A patient intracerebral hemorrhage following : Glasgow coma score &lt; 7 , OR Intracerebral hematoma &gt; 60 cc assess CT MRI 3 . Patients visible , musculoskeletal intraarticular bleed qualify bleed . 4 . Expected survival less 1 month 5 . Recent history ( within 2 week ) diagnose thrombotic event ( TE ) follow : venous thromboembolism , myocardial infarction , disseminate intravascular coagulation ( DIC ) , cerebral vascular accident , transient ischemic attack , unstable angina pectoris hospitalization severe peripheral vascular disease within 2 week prior screen . 6 . Severe sepsis septic shock time Screening . 7 . Pregnant lactate female . 8 . Patient receive follow drug blood product within 7 day Screening : Vitamin K antagonist ( VKA ) Dabigatran Prothrombin Complex Concentrate product ( PCC ) recombinant factor VIIa ( rfVIIa ) Whole blood , plasma fraction 9 . Treated investigational drug &lt; 30 day prior Screening 10 . Planned administration PCC , fresh frozen plasma ( FFP ) rfVIIa Screening within 12 hour end andexanet infusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Factor Xa Inhibitors</keyword>
	<keyword>Major</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Anticoagulant</keyword>
</DOC>